

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. **(withdrawn):** A method for stabilizing an antibody in a solution, which comprises adding glycine and citric acid to the antibody in said solution.
2. **(withdrawn):** The method according to Claim 1, wherein the method of stabilizing suppresses formation of a soluble association and a chemically degraded product of the antibody in the solution.
3. **(withdrawn):** A method for suppressing the formation of a soluble association of an antibody in a solution, which comprises adding glycine to the antibody in said solution.
4. **(withdrawn):** A method for suppressing the formation of a chemically degraded product of an antibody in a solution, which comprises adding citric acid to the antibody in said solution.
5. **(withdrawn):** The method according to any one of Claims 1 to 4, wherein concentration of the antibody in said solution is from 0.01 to 150 mg/mL.
6. **(withdrawn):** The method according to any one of Claims 1 to 3, wherein concentration of glycine in said solution is from 10 to 30 mg/mL.

7. **(withdrawn):** The method according to any one of Claims 1, 2 and 4, wherein concentration of citric acid in said solution is from 0.1 to 50 mmol/L.

8. **(withdrawn):** The method according to Claim 2, wherein the concentration of the antibody in said solution is 0.01 to 150 mg/mL, the concentration of glycine in said solution is 10 to 30 mg/mL and the concentration of citric acid in said solution is 0.1 to 50 mg/mL, said solution further comprising a nonionic surfactant.

9. **(withdrawn):** The method according to Claim 8, wherein the pH of the solution is within the range of 4 to 7.

10. **(withdrawn):** The method according to Claim 9, wherein the antibody is a humanized antibody or a human antibody.

11. **(withdrawn):** The method according to Claim 10, wherein the antibody is an antibody to ganglioside GD3 or an antibody to CCR4.

**12-13. (canceled).**

14. **(currently amended):** A solution-type antibody preparation comprising,  
~~wherein said antibody preparation comprises~~ an antibody, 10 to 30 mg/mL glycine, and 0.1 to 50 mmol/L citric acid, wherein the formation of soluble dimers and trimers of said antibody is inhibited in said preparation.

**15. (previously presented):** The preparation according to Claim 14, wherein the antibody concentration is 0.01 to 150 mg/mL.

**16-17. (canceled).**

**18. (previously presented):** The preparation according to Claim 15, wherein said preparation further comprises a nonionic surfactant.

**19. (previously presented):** The preparation according to Claim 18, wherein said preparation has a pH of between 4 and 7.

**20. (previously presented):** The preparation according to Claim 19, wherein the antibody is a humanized antibody or a human antibody.

**21. (previously presented):** The preparation according to Claim 20, wherein the antibody is an antibody to ganglioside GD3 or an antibody to CCR4.

**22-25. (canceled).**